Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
Portfolio Pulse from Benzinga Newsdesk
Immunic has presented data from its Phase 2 EMPhASIS trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at the 9th Joint ECTRIMS-ACTRIMS Meeting. The data shows improvement in Serum Neurofilament Light Chain (NfL) in both treatment arms of Vidofludimus Calcium over placebo. This is consistent with data from the separate Phase 2 CALLIPER trial of Vidofludimus Calcium in Progressive Multiple Sclerosis.
October 11, 2023 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunic's Phase 2 trial data for Vidofludimus Calcium shows improvement in treating Multiple Sclerosis, which could potentially boost the company's stock.
The positive results from the Phase 2 trial of Vidofludimus Calcium in treating Multiple Sclerosis could potentially lead to increased investor confidence in Immunic, thereby driving up the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100